As cardiovascular clinical trials evolve, imaging biomarkers have become essential tools for enriching patient populations, evaluating therapeutic response and accelerating study timelines. Among these, the detection of coronary inflammation is emerging as a powerful means of advancing research in atherosclerotic cardiovascular disease (ASCVD).
In this upcoming webinar, experts will explore the growing role of imaging endpoints in ASCVD trials, with a focus on the fat attenuation index (FAI) score, a groundbreaking imaging biomarker of coronary inflammation. Attendees will explore how the integration of FAI-based endpoints is set to transform clinical trials in ASCVD.
Attendees will gain an understanding of the scientific basis behind FAI and its validation in large-scale studies. They will learn how this technology enables early disease detection, patient risk stratification and more responsive endpoints. The panel will offer practical guidance into incorporating imaging endpoints into the next generation of ASCVD trials.
The featured speakers will also share insights of best practices in trial planning and execution, including site selection, training and certification, strategies for imaging oversight and data quality assurance.
Register for this webinar today to gain actionable insights on leveraging imaging endpoints to strengthen development strategies in cardiovascular disease trials.
Global Cardiovascular Capabilities
At Medpace, our team of cardiovascular specialists are highly skilled in the scientific methodology, standard of care, evolving regulatory requirements and operational considerations that are necessary to bring drugs and devices that treat or prevent heart disease to market. Our extensive experience in cardiovascular studies and relationships with KOLs paired with our proven track record of success provide the knowledge and flexibility to adapt to the unique needs of each cardiovascular trial.